



**QUEEN'S  
UNIVERSITY  
BELFAST**

## **The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data**

Busby, J., Murchie, P., Murray, L., Iversen, L., Lee, A. J., Spence, A., Watson, M. C., & Cardwell, C. R. (2017). The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data. *International Journal of Cancer*, 140(8), 1828-1835. <https://doi.org/10.1002/ijc.30612>

**Published in:**  
International Journal of Cancer

**Document Version:**  
Peer reviewed version

**Queen's University Belfast - Research Portal:**  
[Link to publication record in Queen's University Belfast Research Portal](#)

### **Publisher rights**

© 2017 UICC.

This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

### **General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

**The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: A nested case-control study of routine Scottish data**

Authors: John Busby PhD<sup>1</sup>, Peter Murchie FRCGP PhD<sup>2</sup>, Liam Murray MFPH MRCGP MD<sup>1</sup>, Lisa Iversen PhD<sup>2</sup>, Amanda J Lee PhD<sup>3</sup>, Andrew Spence MRCP MSc<sup>1</sup>, Margaret C. Watson PhD<sup>4</sup>, Chris R Cardwell PhD<sup>1</sup>

<sup>1</sup> Centre for Public Health, Queen's University Belfast, Belfast, UK

<sup>2</sup> Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK

<sup>3</sup> Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK

<sup>4</sup> Department of Pharmacy and Pharmacology, University of Bath, UK

**Keywords:** risk factors, esophageal cancer, gastric cancer, case-control studies, inflammation

**Article category:** Cancer Epidemiology

**Abbreviations:** PCCIUR: Primary Care Clinical Information Unit Research; OR: odds ratio; CI: confidence interval; MICE: multiple imputation with chained equations

**Novelty and Impact:** This is the first study to investigate the impact of tetracyclines and spironolactone use on gastro-oesophageal cancer risk. Our findings should provide considerable reassurance to the many GPs and patients prescribing or taking these medications. Previous evidence around the effect of bisphosphonates on gastro-oesophageal cancer risk is mixed. Our work provides further evidence of no association, and could suggest that previous findings of positive associations might have been impaired by ascertainment bias.

## Abstract (Structured)

**Purpose:** Bisphosphonate, tetracycline and spironolactone use has been shown to increase gastro-oesophageal inflammation, an accepted risk factor for cancer. We explore whether use of these medications is associated with an increased risk of gastro-oesophageal cancer.

**Methods:** A nested case-control study was conducted using the Primary Care Clinical Information Unit Research (PCCIUR) database from Scotland. Cases with oesophageal or gastric cancer between 1999 and 2011 were matched to up to five controls based on age, gender, year of diagnosis and general practice. Medication use was ascertained using electronic prescribing records. Conditional logistic regression was used to calculate odds ratios (ORs) for the association between medication use and cancer risk after adjustment for comorbidities and other medication use.

**Results:** A similar proportion of gastro-oesophageal cancer cases received bisphosphonates (3.9% vs. 3.5%), tetracycline (6.0% vs. 6.0%) and spironolactone (1.4% vs. 1.1%) compared with the controls. The adjusted ORs for the association between gastro-oesophageal cancer and bisphosphonates, tetracycline and spironolactone were 1.05 (95% CI: 0.85, 1.31), 0.99 (95% CI: 0.84, 1.17) and 1.04 (95% CI: 0.73, 1.49). Further analysis revealed bisphosphonates were associated with increased oesophageal cancer risk (1.34, 95% CI: 1.03, 1.74) but reduced gastric cancer risk (0.71, 95% CI: 0.49, 1.03), although there was no obvious dose-response relationship.

**Conclusions:** There is little evidence that the use of bisphosphonate, tetracycline or spironolactone is associated with increased risk of gastro-oesophageal cancer. Our findings should reassure GPs and patients that these widely-used medications are safe with respect to gastro-oesophageal cancer risk.

## Abstract (Unstructured)

Bisphosphonate, tetracycline and spironolactone use has been shown to increase gastro-oesophageal inflammation, an accepted risk factor for cancer. However, evidence on the effect of these medications on gastro-oesophageal cancer risk are mixed or missing entirely. Therefore, we conducted a nested case-control study using the Primary Care Clinical Information Unit Research (PCCIUR) database from Scotland. Cases with oesophageal or gastric cancer between 1999 and 2011 were matched to up to five controls based on age, gender, year of diagnosis and general practice. Medication use was ascertained using electronic prescribing records. Conditional logistic regression was used to calculate odds ratios (ORs) for the association between medication use and cancer risk after adjustment for comorbidities and other medication use.

A similar proportion of gastro-oesophageal cancer cases received bisphosphonates (3.9% vs. 3.5%), tetracycline (6.0% vs. 6.0%) and spironolactone (1.4% vs. 1.1%) compared with the controls. The adjusted ORs for the association between gastro-oesophageal cancer and bisphosphonates, tetracycline and spironolactone were 1.05 (95% CI: 0.85, 1.31), 0.99 (95% CI: 0.84, 1.17) and 1.04 (95% CI: 0.73, 1.49). Further analysis revealed bisphosphonates were associated with increased oesophageal cancer risk (1.34, 95% CI: 1.03, 1.74) but reduced gastric cancer risk (0.71, 95% CI: 0.49, 1.03), although there was no obvious dose-response relationship. Overall, there is little evidence that the use of bisphosphonate, tetracycline or spironolactone is associated with increased risk of gastro-oesophageal cancer. Our findings should reassure GPs and patients that these widely-used medications are safe with respect to gastro-oesophageal cancer risk.

## Introduction

Oesophageal and gastric cancer are among the most common cancers in the world with around 456,000 and 952,000 new cases diagnosed annually.<sup>1</sup> Prognosis is extremely poor, even in OECD countries such as the UK, where around 55% of patients die within one year of diagnosis.<sup>2</sup> Those who survive suffer marked reduction in their quality of life during treatment and recovery.<sup>3-5</sup> Inflammation is a well-established risk factor for cancer and various mechanisms have been proposed to explain this connection.<sup>6, 7</sup> Several studies have demonstrated that patients with reflux oesophagitis have much higher oesophageal cancer risk<sup>8</sup>, most likely through the Barrett's pathway.<sup>9, 10</sup> It is also well recognised that chronic gastric inflammation, for example due to *H. pylori* infection, may progress to atrophy (e.g. ulceration), metaplasia, dysplasia, and gastric cancer.<sup>11, 12</sup>

Bisphosphonates, tetracyclines and spironolactone are widely used medications with main indications of osteoporosis, infections/acne/rosacea and hypertension/cardiac failure, respectively. During 2015, approximately 8.2, 3.2 and 2.5 million were prescribed by English general practitioners.<sup>13</sup> Long-term usage of these medications is common; for example the anti-fracture effects of some bisphosphonates are only realised after 36 months<sup>14</sup> and tetracycline treatment for acne can last indefinitely.<sup>15</sup> Each of these medications has been associated with increased risk of gastro-oesophageal inflammation. Specifically, bisphosphonates have been shown in case reports to cause severe esophagitis including inflammation and thickening of the oesophageal wall<sup>16, 17</sup> Tetracyclines have also been shown to cause oesophagitis<sup>18, 19</sup> with prospective studies finding an increased risk of oesophageal injury and ulceration<sup>20</sup>, and case reports demonstrating tetracycline induced lesions.<sup>21</sup> Similarly, spironolactone has been associated with inflammation of the stomach including increased risk of gastric ulcers<sup>22</sup>, possibly due to impaired mucosal healing.<sup>22, 23</sup> Despite the widespread and prolonged use of these medications, epidemiological studies have focussed solely on bisphosphonates and gastro-oesophageal cancer risk<sup>24</sup>, and have yet to investigate the risk associated with tetracyclines and spironolactone use.

Therefore, in a case-control study nested within a population-based primary care cohort from Scotland, we investigated whether bisphosphonates, tetracyclines or spironolactone were associated with an increased risk of gastro-oesophageal cancer.

## Methods

### Data

We conducted a nested case-control study using the Primary Care Clinical Information Unit Research (PCCIUR) database.<sup>25</sup> Between 1993 and 2011, the PCCIUR collected computerised medical records from approximately 15% of the Scottish general practice population, and includes details on patient demographics (e.g. age, deprivation), primary care encounters, clinical diagnoses and prescriptions. Access to the PCCIUR data was approved by the Research Applications and Data Management Team, University of Aberdeen. Ethical approval for this study was supplied by the Queen's University Belfast, School of Medicine Ethics Committee (reference number: 15.43).

### Cases and controls

Our primary outcome was gastro-oesophageal cancer since classifying tumours arising close to the oesophagogastric junction is difficult, and guidance on this process evolved throughout the study period.<sup>26, 27</sup> However, separate site-specific estimates for oesophageal and gastric cancer were also presented. Cases were defined as patients with a first-time oesophageal (Read code: B10..) or gastric (Read code: B11..) cancer diagnosis after 1<sup>st</sup> January 1999 and before 30<sup>th</sup> April 2011. Up to five controls were randomly selected for each case matched on age, gender, year of diagnosis and general practice. The index date was defined as the diagnosis date of the case in each matched group. The start of the exposure period was the latest of 1<sup>st</sup> January 1996 (as prescriptions before this were less likely to be generated electronically) or the date of general practice registration. Additionally, the exposure period was truncated to ensure it was identical across the matched groups.<sup>28</sup> Cases and controls with an earlier cancer diagnosis (other than non-melanoma skin cancer), and those with less than three years of exposure prior to index date, were excluded from the matching process.

### Definition of exposure

We identified prescriptions of bisphosphonates, tetracyclines and spironolactone from electronic prescription records. We used the British National Formulary (August 2016 version) to compile a list of proprietary and generic drug names containing these compounds (Appendix 1). We excluded prescriptions before 1<sup>st</sup> January 1996 and those in the year prior to the index date (to prevent reverse causation). We defined patients as users if they had at least one prescription during the exposure period. To enable the testing of dose-response relationships we calculated the total number of prescriptions received during the exposure period and split patients into lower (less than the median) and higher (more than the median) users. We conducted a separate analysis for

nitrogen-containing bisphosphonates, as these have a mechanism of action distinct from non-nitrogen containing products<sup>29</sup>, and alendronate, which has been previously linked to cases of esophageal cancer.<sup>30</sup>

### Confounding factors

We identified eleven comorbidities (myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease, liver disease) using Read codes recorded by the GP during the exposure period.<sup>31</sup> Use of aspirin and statins within the exposure period were identified from prescription records (Appendix 1) as associations with oesophageal and/or gastric cancer have been identified previously.<sup>32, 33</sup> Lifestyle data including obesity (BMI>30), smoking status (never, ex, current) and alcohol use (none, low [e.g. moderate or light drinker], high [e.g. above recommended limits, chronic alcoholism]) were also recorded in the PCCIUR data using Read codes.

### Statistical Analysis

We calculated descriptive statistics and compared the demographics and clinical characteristics of the cases and controls. We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the association between medication use and gastro-oesophageal cancer. The matched design of the study accounted for the effect of age, gender, general practice and year of diagnosis with additional adjustments were made for statin use (yes/no), aspirin use (yes/no) and the presence of each comorbidity (yes/no) using regression.

We performed additional sensitivity analysis to investigate the impact of additionally adjusting for smoking, alcohol consumption and obesity using complete case and multiple imputation with chained equations (MICE) methods. The imputation used ordered logit models with age, gender and deprivation, separately for cases and controls. Briefly, MICE is a simulation-based approach for handling missing data which leads to valid statistical inferences.<sup>34</sup> Sensitivity analyses were also conducted investigating the impact of excluding prescriptions in the two years prior to the index date (as opposed to one in the main analysis) and defining medication users as patients with at least three prescriptions (as opposed to one in the main analysis). Analyses was conducted using Stata version 13.<sup>35</sup>

## Results

We identified 3,098 cases of gastro-oesophageal cancer (1,979 oesophageal and 1,119 gastric cancer) (Table 1). An average of 4.8 controls existed for each case with a median exposure period of 5.5 years (min 3.0, max 15.1). There were some potentially important differences between cases and controls. Most notably, a larger proportion of cases had a history of COPD (11.7% vs 8.5%), and were more likely to be current or ex-smokers (64.7% vs 55.3%), drink high levels of alcohol (7.5% vs. 5.3%) and have a BMI under thirty (85.8% vs 79.9%). The proportion of missing data for smoking status and alcohol consumption was 21.5% and 32.0% respectively.

Overall, 3.9% (122/3098) of cases and 3.5% (526/14937) of controls used bisphosphonates suggesting little association between bisphosphonate use and gastro-oesophageal cancer risk ( $OR_{adj}=1.05$ ; 95% CI: 0.85, 1.31) (Table 2). There was evidence of a 34% increased risk ( $OR_{adj}=1.34$ ; 95% CI: 1.03, 1.74) of oesophageal cancer in bisphosphonate users but a reduction of 29% ( $OR_{adj}=0.71$ ; 95% CI: 0.49, 1.03) in gastric cancer. The association between bisphosphonate use and oesophageal or gastric cancer did not appear to follow a dose-response relationship.

Tetracycline was used by 6.0% (186/3098) of cases and 6.0% (894/14937) of controls; there was no evidence of association with gastro-oesophageal cancer risk ( $OR_{adj}=0.99$ ; 95% CI: 0.84, 1.17). Similarly, little associations were observed between tetracycline use and oesophageal ( $OR_{adj}=1.01$ ; 95% CI: 0.82, 1.25) and gastric cancer ( $OR_{adj}=0.96$ ; 95% CI: 0.73, 1.28).

Overall, 1.4% (43/3098) of cases and 1.1% (159/14937) of controls used spironolactone but there were small associations with gastro-oesophageal cancer risk after adjustment for confounders ( $OR_{adj}=1.04$ ; 95% CI: 0.73, 1.49). Again, there was little evidence of higher risk for oesophageal or gastric cancer alone, with adjusted odds ratios of 1.04 (95% CI: 0.68, 1.61) and 1.05 (95% CI: 0.55, 2.00) respectively.

In general, our conclusions were little altered in sensitivity analyses (Table 3). Similar associations were observed when excluding prescriptions in the two years prior to diagnosis rather than one (to reduce the risk of reverse causality), and when the exposure definition of 'ever use' was based upon three or more prescriptions rather than one. Additionally adjusting for lifestyle factors (smoking, alcohol consumption, and obesity), either in a complete case analysis or when using MICE, resulted in similar estimates to the main analysis. We also found slightly larger, although still moderate, associations when restricting our analysis to nitrogen-containing bisphosphonates ( $OR_{adj}=1.15$ ; 95%



CI: 0.90, 1.46), or alendronate alone ( $OR_{adj} = 1.13$ ; 95% CI: 0.87, 1.46), compared to the main analysis which combined all bisphosphonates.

## Discussion

In this study of oesophageal and gastric cancer cases and controls in a community-based population, we found little evidence of an association between gastro-oesophageal cancer risk and the use of bisphosphonates, tetracyclines or spironolactone. Although there was some evidence that bisphosphonates increased the risk of oesophageal cancer, there was no obvious dose-response relationship and these increases were largely offset by a reduction in gastric cancer risk.

### Strengths and limitations

The main strength of our study lies in the high-quality and nationally representative data on which it is based.<sup>36</sup> It is the first study to investigate the effect of tetracycline and spironolactone on gastro-oesophageal cancer risk and has found no evidence of an increased incidence, which is important and reassuring given the large numbers of patients who use these medications often for prolonged periods of time. We used prescribing data collected as part of routine clinical care, in many cases, several years before the onset of oesophageal or gastric cancer which accurately reflects GP prescribing practices and negates the risk of recall bias. Although a weakness of this approach is that we do not know if patients used their prescribed medications, the main conclusions were similar when restricting our analysis to patients who received multiple repeat prescriptions (>12) where non-compliance is likely to be less of an issue. Additionally, GP records do not contain data on over-the-counter medications which may have impaired our ability to accurately adjust for aspirin use (due to exposure misclassification).

Our study is observational and hence open to confounding; although we have controlled for several of the key determinants of cancer risk through the matched design and analysis (e.g. age, comorbidities and general practice) some other risk factors, including ethnicity and nutrition, were not available. This could be a particular concern in the bisphosphonate analysis, as patients with osteoporosis may be more likely to report upper gastrointestinal disorders, even prior to bisphosphonate initiation.<sup>37</sup> Our analysis is based on GP diagnosed cancer. Although a recent CPRD study found that over 95% of gastro-oesophageal cancers are captured within GP records<sup>38</sup>, a higher proportion of oesophageal cancers were recorded in the Scottish Cancer Registry<sup>39</sup> than the PCCIUR data, which could suggest some misclassification of cancer site in our study. This potential issue would not affect our primary analysis which combined oesophageal and gastric cancers. Finally, histological data were not available to allow a separate analysis of squamous cell carcinoma and adenocarcinoma, the two most common forms of oesophageal cancer.

## Comparisons with other research

To our knowledge, this is the first study to investigate the impact of tetracyclines and spironolactone use on gastro-oesophageal cancer risk.

Several studies have previously examined the effect of bisphosphonates on gastro-oesophageal cancer risk. In agreement with our findings, two UK-based studies which combined the oesophageal and gastric cancer sites together in a single analysis found no significant association<sup>40, 41</sup> with bisphosphonate use, while another Danish study reported a 37% decrease in risk.<sup>42</sup> Although a recent meta-analysis reported no significant association between bisphosphonate use and oesophageal cancer risk<sup>24</sup>, several individual studies have observed an association. For example, one UK-based study reported a 30% increased risk of oesophageal cancer among bisphosphonate users, which was similar to the 34% effect size estimated in our study.<sup>43, 44</sup> Our finding of reduced gastric cancer incidence among bisphosphonate users was replicated by several other studies<sup>43-45</sup>, including one which found a 39% reduction in the risk of gastric cancer<sup>42</sup>, although a recent meta-analysis reported no overall effect.<sup>24</sup> Several studies investigating the effect of bisphosphonate use on cancer incidence, separately for both the oesophageal and gastric sites, reported a similar pattern to our study (i.e. increased risk of oesophageal cancer which was largely offset by a decreased risk of gastric cancer).<sup>43-45</sup>

## Implications

Bisphosphonate, tetracycline and spironolactone are widely used and effective treatments for a range of indications including osteoporosis, infections/acne/rosacea and hypertension/cardiac failure respectively. Our study suggests that any inflammation caused by these medications does not substantially increase the risk of gastro-oesophageal cancer, and GPs or patients should not be unduly concerned about cancer risk when prescribing or taking these treatments.

It is unclear why bisphosphonate users had an increased risk of oesophageal cancer in our study. Firstly, these results could represent a true causal association; bisphosphonates are well known to cause dyspepsia and other inflammatory changes (e.g. oesophagitis, mucosal abnormalities)<sup>46</sup> which could form an important part of the upper-gastrointestinal cancer pathway.<sup>30</sup> Perhaps more likely, particularly given our concurrent finding of lower gastric cancer risk among bisphosphonate users, is that these associations are at least partly driven by a form of ascertainment bias. One Danish study

reported that, due to higher rates of gastrointestinal side effects, patients receiving bisphosphonates were more than twice as likely to undergo upper endoscopy (4.1% vs. 1.7%).<sup>42</sup> This could lead to earlier detection of oesophageal cancer and more accurate classification of some oesophageal tumours proximal to the oesophagogastric junction in bisphosphonate users, which would have otherwise been incorrectly recorded as gastric in origin.<sup>42</sup>

## Conclusions

Overall, our study provided little evidence that the use of bisphosphonate, tetracyclines or spironolactone are associated with increased risk of gastro-oesophageal cancer. These findings should reassure GPs and patients that these widely-used medications are safe with respect to gastro-oesophageal cancer risk.

## References

1. GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, 2012.
2. Office for National Statistics. Cancer survival in England: Patients diagnosed between 2010 and 2014 and followed up to 2015, vol. 2016, 2016.
3. Zieren HU, Jacobi CA, Zieren J, Muller JM. Quality of life following resection of oesophageal carcinoma. *Br J Surg* 1996;**83**: 1772-5.
4. Viklund P, Wengstrom Y, Rouvelas I, Lindblad M, Lagergren J. Quality of life and persisting symptoms after oesophageal cancer surgery. *Eur J Cancer* 2006;**42**: 1407-14.
5. Yu W, Park KB, Chung HY, Kwon OK, Lee SS. Chronological Changes of Quality of Life in Long-Term Survivors after Gastrectomy for Gastric Cancer. *Cancer Res Treat* 2016;**48**: 1030-6.
6. Mantovani A, Marchesi F, Portal C, Allavena P, Sica A. Linking inflammation reactions to cancer: novel targets for therapeutic strategies. *Advances in experimental medicine and biology* 2008;**610**: 112-27.
7. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. *Seminars in cancer biology* 2012;**22**: 33-40.
8. Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye WM, Gammon MD, Risch HA, Casson AG, Freedman ND, Chow WH, Wu AH, et al. Gastroesophageal Reflux in Relation to Adenocarcinomas of the Esophagus: A Pooled Analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). *PloS one* 2014;**9**: 11.
9. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma--a population-based cohort study. *The American journal of gastroenterology* 2006;**101**: 1193-9.
10. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. *Gut* 2004;**53**: 1070-4.
11. Hansson LE, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, Fraumeni JF, Adami HO. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. *New England Journal of Medicine* 1996;**335**: 242-9.
12. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *New England Journal of Medicine* 2001;**345**: 784-9.
13. Powell-Smith A, Goldacre B. OpenPrescribing.net, 2016.
14. Russell RG, Watts NB, Ebtino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2008;**19**: 733-59.
15. Dreno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H. European recommendations on the use of oral antibiotics for acne. *European journal of dermatology : EJD* 2004;**14**: 391-9.
16. Ryan JM, Kelsey P, Ryan BM, Mueller PR. Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. *Radiology* 1998;**206**: 389-91.
17. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK. Esophagitis associated with the use of alendronate. *The New England journal of medicine* 1996;**335**: 1016-21.
18. Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M. Drug-induced esophagitis. *Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus* 2009;**22**: 633-7.
19. Gencosmanoglu R, Kurtkaya-Yapicier O, Tiftikci A, Avsar E, Tozun N, Oran ES. Mid-esophageal ulceration and candidiasis-associated distal esophagitis as two distinct clinical patterns

of tetracycline or doxycycline-induced esophageal injury. *Journal of clinical gastroenterology* 2004;**38**: 484-9.

20. Alvares JF, Kulkarni SG, Bhatia SJ, Desai SA, Dhawan PS. Prospective evaluation of medication-induced esophageal injury and its relation to esophageal function. *Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology* 1999;**18**: 115-7.

21. Tahan V, Sayrak H, Bayar N, Erer B, Tahan G, Dane F. Doxycycline-induced ulceration mimicking esophageal cancer. *Cases journal* 2008;**1**: 144-.

22. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. *BMJ (Clinical research ed)* 2006;**333**: 330.

23. Doll R, Langman MJ, Shawdon HH. Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone. *Gut* 1968;**9**: 42-5.

24. Wright E, Schofield PT, Molokhia M. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis. *BMJ Open* 2015;**5**.

25. The Institute of Applied Health Sciences. PCCIU Background, 2016.

26. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas. *The American journal of surgical pathology* 2007;**31**: 569-75.

27. Rüdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients. *Annals of Surgery* 2000;**232**: 353-61.

28. Suissa S, Dell'aniello S, Vahey S, Renoux C. Time-window bias in case-control studies: statins and lung cancer. *Epidemiology (Cambridge, Mass)* 2011;**22**: 228-31.

29. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. *Mayo Clinic proceedings Mayo Clinic* 2008;**83**: 1032-45.

30. Wysowski DK. Reports of Esophageal Cancer with Oral Bisphosphonate Use. *New England Journal of Medicine* 2009;**360**: 89-90.

31. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. *BMC Family Practice* 2010;**11**: 1-.

32. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. *Br Med J* 2010;**340**: 12.

33. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 2011;**377**: 31-41.

34. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Statistics in medicine* 2011;**30**: 377-99.

35. StataCorp. Stata Statistical Software: Release 13 College Station, TX: StataCorp LP, 2013.

36. Elder R, Kirkpatrick M, Ramsay W, Macleod M, Guthrie B, Sutton M, Watt G. Measuring quality in primary medical services using data from SPICE, 2007.

37. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Gastric and esophagus events before and during treatment of osteoporosis. *Calcified tissue international* 2010;**86**: 110-5.

38. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. *Pharmacoepidemiology and drug safety* 2013;**22**: 168-75.

39. (Scotland) ISD. Cancer Statistics, vol. 2016.

40. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. *Jama* 2010;**304**: 657-63.

41. Wright E, Schofield PT, Seed P, Molokhia M. Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD). *PloS one* 2012;**7**: e47616.

42. Abrahamsen B, Pazianas M, Eiken P, Russell RGG, Eastell R. Esophageal and gastric cancer incidence and mortality in alendronate users. *Journal of Bone and Mineral Research* 2012;**27**: 679-86.
43. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. *BMJ (Clinical research ed)* 2010;**341**: c4444.
44. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. *BMJ (Clinical research ed)* 2013;**346**: f114.
45. Lee W-Y, Sun L-M, Lin M-C, Liang J-A, Chang S-N, Sung F-C, Muo C-H, Kao C-H. A Higher Dosage of Oral Alendronate Will Increase the Subsequent Cancer Risk of Osteoporosis Patients in Taiwan: A Population-Based Cohort Study. *PloS one* 2013;**7**: e53032.
46. Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. *Human Pathology* 2007;**38**: 527-36.

## Tables and Figures

**Table 1: Characteristics of controls and cases with oesophageal or gastric cancer**

	Cases	Controls
<b>Count</b>	3,098	14,937
<b>Median Exposure Years (Min, Max)</b>	5.5 (3.0, 15.1)	5.5 (3.0, 15.1)
<b>Year of Diagnosis</b>		
1999-2003	1,063 (34.3%)	5,151 (34.5%)
2004-2007	1,404 (45.3%)	6,741 (45.1%)
2008-2011	631 (20.4%)	3,045 (20.4%)
<b>Mean Age (SD)</b>	69.6 (11.3)	69.1 (11.2)
0-39	26 (0.8%)	133 (0.9%)
40-59	563 (18.2%)	2,807 (18.8%)
60-79	1,886 (60.9%)	9,269 (62.1%)
80+	623 (20.1%)	2,728 (18.3%)
<b>Sex</b>		
Female	1,095 (35.3%)	5,287 (35.4%)
Male	2,003 (64.7%)	9,650 (64.6%)
<b>Smoking status</b>		
Non-smoker	931 (35.3%)	5,147 (44.7%)
Ex-smoker	898 (34.0%)	3,656 (31.8%)
Current smoker	811 (30.7%)	2,708 (23.5%)
Missing	458	3,426
<b>Alcohol Consumption</b>		
No	551 (24.4%)	2,338 (23.3%)
Low	1,534 (68.1%)	7,145 (71.3%)
High	169 (7.5%)	532 (5.3%)
Missing	844	4,922
<b>Obesity</b>		
Not Obese	2,658 (85.8%)	11,932 (79.9%)
Obese	440 (14.2%)	3,005 (20.1%)
<b>Deprivation Quintile</b>		
1 (Least Deprived)	375 (12.3%)	1,776 (12.0%)
2	555 (18.1%)	2,657 (18.0%)
3	648 (21.2%)	3,137 (21.3%)
4	748 (24.4%)	3,637 (24.6%)
5 (Most Deprived)	734 (24.0%)	3,549 (24.1%)
Missing	38	181
<b>Common Comorbidities<sup>a</sup></b>		
Connective Tissue Disease	1,377 (44.4%)	6,752 (45.2%)
Diabetes	328 (10.6%)	1,422 (9.5%)
COPD	361 (11.7%)	1,267 (8.5%)
CVD	283 (9.1%)	1,214 (8.1%)
MI	272 (8.8%)	1,181 (7.9%)
<b>Other Drug Use</b>		
Aspirin	915 (29.5%)	4,217 (28.2%)
Statin	753 (24.3%)	3,367 (22.5%)

<sup>a</sup> For brevity only the 5 most common comorbidities are listed. The full analysis included myocardial infarction (MI), heart failure, peripheral vascular disease, cerebrovascular disease (CVD), connective tissue disease, dementia, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, diabetes, renal disease and liver disease



**Table 2: Combined analysis of drug use risk with oesophageal and gastric cancer risk**

	Cases	Controls	Unadjusted OR (95% CI)	Adjusted OR (95% CI) <sup>b</sup>
<b>Gastro-oesophageal combined</b>				
<b>Bisphosphonates</b>				
Never	2,976 (96.1%)	14,411 (96.5%)	Ref	Ref
Ever	122 (3.9%)	526 (3.5%)	1.09 (0.88,1.34)	1.05 (0.85,1.31)
Lower Usage (1-18 prescriptions)	64 (2.1%)	249 (1.7%)	1.22 (0.92,1.61)	1.16 (0.87,1.55)
Higher Usage (19+)	58 (1.9%)	277 (1.9%)	0.97 (0.72,1.31)	0.95 (0.71,1.29)
<b>Tetracycline</b>				
Never	2,912 (94.0%)	14,043 (94.0%)	Ref	Ref
Ever	186 (6.0%)	894 (6.0%)	1.01 (0.86,1.20)	0.99 (0.84,1.17)
Lower Usage (1)	104 (3.4%)	542 (3.6%)	0.93 (0.75,1.16)	0.92 (0.74,1.14)
Higher Usage (2+)	82 (2.6%)	352 (2.4%)	1.14 (0.89,1.45)	1.10 (0.86,1.42)
<b>Spironolactone</b>				
Never	3,055 (98.6%)	14,778 (98.9%)	Ref	Ref
Ever	43 (1.4%)	159 (1.1%)	1.24 (0.88,1.75)	1.04 (0.73,1.49)
Lower Usage (1-10)	21 (0.7%)	77 (0.5%)	1.26 (0.77,2.05)	1.10 (0.67,1.81)
Higher Usage (11+)	22 (0.7%)	82 (0.5%)	1.23 (0.76,1.98)	0.99 (0.60,1.62)
<b>Oesophageal</b>				
<b>Bisphosphonates</b>				
Never	1,895 (95.8%)	9,254 (97.0%)	Ref	Ref
Ever	84 (4.2%)	289 (3.0%)	1.40 (1.08,1.81)	1.34 (1.03,1.74)
Lower Usage (1-18)	47 (2.4%)	127 (1.3%)	1.78 (1.25,2.51)	1.70 (1.20,2.43)
Higher Usage (19+)	37 (1.9%)	162 (1.7%)	1.09 (0.75,1.58)	1.04 (0.71,1.52)
<b>Tetracycline</b>				
Never	1,858 (93.9%)	8,976 (94.1%)	Ref	Ref
Ever	121 (6.1%)	567 (5.9%)	1.04 (0.85,1.29)	1.01 (0.82,1.25)
Lower Usage (1)	66 (3.3%)	341 (3.6%)	0.95 (0.72,1.24)	0.93 (0.70,1.22)
Higher Usage (2+)	55 (2.8%)	226 (2.4%)	1.19 (0.88,1.61)	1.14 (0.83,1.55)
<b>Spironolactone</b>				
Never	1,949 (98.5%)	9,436 (98.9%)	Ref	Ref
Ever	30 (1.5%)	107 (1.1%)	1.27 (0.84,1.92)	1.04 (0.68,1.61)
Lower Usage (1-10)	13 (0.7%)	55 (0.6%)	1.05 (0.57,1.95)	0.94 (0.50,1.75)
Higher Usage (11+)	17 (0.9%)	52 (0.5%)	1.50 (0.86,2.61)	1.15 (0.64,2.06)
<b>Gastric</b>				
<b>Bisphosphonates</b>				
Never	1,081 (96.6%)	5,157 (95.6%)	Ref	Ref
Ever	38 (3.4%)	237 (4.4%)	0.72 (0.50,1.04)	0.71 (0.49,1.03)
Lower Usage (1-18)	17 (1.5%)	122 (2.3%)	0.65 (0.39,1.08)	0.62 (0.37,1.04)
Higher Usage (19+)	21 (1.9%)	115 (2.1%)	0.80 (0.49,1.29)	0.80 (0.49,1.31)
<b>Tetracycline</b>				
Never	1,054 (94.2%)	5,067 (93.9%)	Ref	Ref
Ever	65 (5.8%)	327 (6.1%)	0.96 (0.72,1.27)	0.96 (0.73,1.28)
Lower Usage (1)	38 (3.4%)	201 (3.7%)	0.90 (0.63,1.29)	0.92 (0.64,1.31)
Higher Usage (2+)	27 (2.4%)	126 (2.3%)	1.04 (0.68,1.59)	1.04 (0.68,1.59)
<b>Spironolactone</b>				
Never	1,106 (98.8%)	5,342 (99.0%)	Ref	Ref
Ever	13 (1.2%)	52 (1.0%)	1.18 (0.63,2.21)	1.05 (0.55,2.00)
Lower Usage (1-10)	8 (0.7%)	22 (0.4%)	1.78 (0.78,4.08)	1.53 (0.66,3.57)
Higher Usage (11+)	5 (0.4%)	30 (0.6%)	0.75 (0.29,1.98)	0.71 (0.27,1.87)

<sup>b</sup> Adjusted for statin and aspirin use, and the presence of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease and liver disease. Additionally conditioned on age, general practice and year of diagnosis

**Table 3: Sensitivity analysis**

	Cases	Controls	Unadjusted OR (95% CI)	Adjusted OR (95% CI) <sup>c</sup>
<b>Bisphosphonates</b>				
<b>2- year exposure lag</b>				
Never	3,001 (96.9%)	14,520 (97.2%)	Ref	Ref
Ever	97 (3.1%)	417 (2.8%)	1.09 (0.86,1.37)	1.04 (0.82,1.33)
<b>Ever use ≥3 prescriptions</b>				
Never	2,988 (96.4%)	14,442 (96.7%)	Ref	Ref
Ever	110 (3.6%)	495 (3.3%)	1.05 (0.84,1.30)	1.01 (0.81,1.26)
<b>MI<sup>d</sup> lifestyle adjusted</b>				
Never	2,976 (96.1%)	14,411 (96.5%)	Ref	Ref
Ever	122 (3.9%)	526 (3.5%)	1.09 (0.88,1.34)	1.03 (0.83,1.28)
<b>Lifestyle complete case</b>				
Never	2,123 (96.0%)	9,218 (96.2%)	Ref	Ref
Ever	88 (4.0%)	369 (3.8%)	1.00 (0.77,1.29)	0.93 (0.71,1.21)
<b>Nitrogen containing bisphosphonates</b>				
Never	3,001 (96.9%)	14,551 (97.4%)	Ref	Ref
Ever	97 (3.1%)	386 (2.6%)	1.18 (0.93,1.50)	1.15 (0.90,1.46)
<b>Alendronate only</b>				
Never	3,015 (97.3%)	14,603 (97.8%)	Ref	Ref
Ever	83 (2.7%)	334 (2.2%)	1.17 (0.91,1.51)	1.13 (0.87,1.46)
<b>Tetracycline</b>				
<b>2- year exposure lag</b>				
Never	2,933 (94.7%)	14,200 (95.1%)	Ref	Ref
Ever	165 (5.3%)	737 (4.9%)	1.10 (0.92,1.31)	1.07 (0.89,1.28)
<b>Ever use ≥3 prescriptions</b>				
Never	3,049 (98.4%)	14,718 (98.5%)	Ref	Ref
Ever	49 (1.6%)	219 (1.5%)	1.10 (0.80,1.50)	1.05 (0.76,1.45)
<b>MI lifestyle adjusted</b>				
Never	2,912 (94.0%)	14,043 (94.0%)	Ref	Ref
Ever	186 (6.0%)	894 (6.0%)	1.01 (0.86,1.20)	1.02 (0.86,1.20)
<b>Lifestyle complete case</b>				
Never	2,067 (93.5%)	8,914 (93.0%)	Ref	Ref
Ever	144 (6.5%)	673 (7.0%)	0.93 (0.76,1.13)	0.92 (0.75,1.13)
<b>Spirolactone</b>				
<b>2- year exposure lag</b>				
Never	3,069 (99.1%)	14,805 (99.1%)	Ref	Ref
Ever	29 (0.9%)	132 (0.9%)	1.02 (0.68,1.53)	0.82 (0.54,1.26)
<b>Ever use ≥3 prescriptions</b>				
Never	3,061 (98.8%)	14,802 (99.1%)	Ref	Ref
Ever	37 (1.2%)	135 (0.9%)	1.26 (0.87,1.83)	1.05 (0.72,1.54)
<b>MI lifestyle adjusted</b>				
Never	3,055 (98.6%)	14,778 (98.9%)	Ref	Ref
Ever	43 (1.4%)	159 (1.1%)	1.24 (0.88,1.75)	1.09 (0.76,1.57)
<b>Lifestyle complete case</b>				
Never	2,175 (98.4%)	9,478 (98.9%)	Ref	Ref
Ever	36 (1.6%)	109 (1.1%)	1.25 (0.83,1.89)	1.10 (0.72,1.69)

<sup>c</sup> Adjusted for statin and aspirin use, and the presence of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease and liver disease. Additionally conditioned on age, general practice and year of diagnosis

<sup>d</sup> Multiple imputation with chained equations for smoking, alcohol consumption and obesity with age, gender and deprivation used in the imputation, separately for cases and controls, using chained ordered logit models

## Appendices

### Appendix 1: List of generic and proprietary drug names for each exposure and confounder medication

Substance Name	Drug Name
<b>Aspirin</b>	Asasantin, Aspirin, Caprin, Co-codaprin, Micropirin, Migramax, Nu-Seals
<b>Bisphosphonates</b>	Aclasta, Actonel, Alendronic acid, Aredia, Binosto, Bondronat, Bonefos, Bonviva, Clasteon, Clodronate, Didronel, Didronel PMO, Fosamax, Fosavance, lasibon, Ibrandronic acid, Loron, Pamidronate, Risedronate, Zoledronic acid, Zometa
<b>Spironolactone</b>	Aldactide, Aldactone, Co-flumactone, Lasilactone, Spironolactone
<b>Statin</b>	Atorvastatin, Cholib, Crestor, Dorisin, Fluvastatin, Inegy, Lescol, Lipitor, Lipostat, Luvinsta, Pinmactil, Pravastatin, Rosuvastatin, Simvador, Simvastatin, Stefluvlin, Zocor
<b>Tetracycline</b>	Acnamino, Aknemin, Democlocyline, Doxycycline, Doxylar, Efracea, Lymecycline, Minocin, Minocycline, Oxymycin, Oxytetracycline, Sebomin, Tetracycline, Tetralysal, Tigecycline, Tygacil, Vibramycin-D